New Reference: Periop FLOT in Esophageal Cancer
Study
Phase 3, multicenter, randomized, controlled trial (ESOPEC)
|
Esophageal or GE junction adenoCa, cT1cN+, cT2–4a cN+, or cT2–4a cN0
|
FLOT (perioperative chemotherapy) vs. preoperative chemoradiotherapy
|
Efficacy
3-yr OS: 57.4% vs. 50.7% (FLOT vs. preoperative chemoradiotherapy) (HR: 0.70 [0.53-0.92])
|
5-yr OS: 50.6% vs. 38.7%
|
mOS: 66 mos (95% CI, 36 to NE) vs. 37 mos (95% CI, 28 to 43)
|
3-yr PFS: 51.6% vs. 35.0% (HR: 0.66 [0.51-0.85])
|
Pathological CR (ypT0 ypN0): 16.7% vs. 10.1%
|
Safety
Grade ≥3 AEs: Neutropenia (19.8% vs. NA), diarrhea (6.8% vs. NA), leukopenia (6.3% vs. 9.7%), pneumonia (5.8% vs. 9.2%)
|
Serious AEs: 47.3% vs. 41.8%
|
Treatment-related 90-day mortality: 3.1% vs. 5.6%
|
Hoeppner J,Brunner T,Schmoor C Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
Reviewed by Ulas D. Bayraktar, MD on Jan 24, 2025
